疫苗与黑色素瘤

Vaccines and melanoma.

作者信息

Ott Patrick A, Fritsch Edward F, Wu Catherine J, Dranoff Glenn

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Melanoma Disease Center, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Center for Immuno-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02215, USA.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, MA 02142, USA.

出版信息

Hematol Oncol Clin North Am. 2014 Jun;28(3):559-69. doi: 10.1016/j.hoc.2014.02.008. Epub 2014 Apr 3.

DOI:10.1016/j.hoc.2014.02.008

PMID:24880947

Abstract

The potential for therapeutic efficacy of a melanoma vaccine has been evident preclinically for many years. In melanoma patients, vaccines have resulted in the induction of immune responses, although clinical benefit has not been clearly documented. The recent achievements with immune-checkpoint blockade have shown that immunotherapy can be a powerful tool in cancer therapy. With increased understanding of tumor immunity, the limitations of previous cancer vaccination approaches have become evident. Rapid progress in technologies that enable better vaccine design raise the expectation that these limitations can be overcome, thus leading to a clinically effective melanoma vaccine in the near future.

摘要

多年来，黑色素瘤疫苗的治疗效果潜力在临床前研究中已很明显。在黑色素瘤患者中，疫苗已能诱导免疫反应，尽管临床获益尚未得到明确证实。免疫检查点阻断的最新成果表明，免疫疗法可以成为癌症治疗中的有力工具。随着对肿瘤免疫认识的增加，以往癌症疫苗接种方法的局限性变得明显。能够实现更好疫苗设计的技术的快速进步，让人期待这些局限性能够被克服，从而在不久的将来带来临床有效的黑色素瘤疫苗。